107 filings
Page 3 of 6
8-K
u6hnd
10 May 22
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
8:05am
DEFA14A
1spsfsk3b2wk2wdu6 jl
29 Apr 22
Additional proxy soliciting materials
8:01am
8-K
kjunb p8t
8 Apr 22
Departure of Directors or Certain Officers
4:30pm
S-8
km9 vgw06588cwcztd
17 Mar 22
Registration of securities for employees
4:31pm
8-K
3n2pglpmufz lm
16 Mar 22
Prelude Therapeutics Reports Full Year 2021 Financial Results
8:05am
8-K
lys5do
9 Mar 22
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
8:22am
8-K
ujuukl
16 Feb 22
Regulation FD Disclosure
5:03pm
8-K
mh1 ifnky
10 Jan 22
Regulation FD Disclosure
7:02am
8-K
aj4vex8fckov10gh
3 Dec 21
Entry into a Material Definitive Agreement
9:00am
EFFECT
4j7ws zgx2i
26 Nov 21
Notice of effectiveness
12:15am
CORRESP
lsnl ht3w1f63tfgv
22 Nov 21
Correspondence with SEC
12:00am
UPLOAD
3bjnz3joijns7ks 7d
19 Nov 21
Letter from SEC
12:00am
S-3
nbbmtsu6bnpqyc0r 67
12 Nov 21
Shelf registration
4:02pm
8-K
uzba3aee
12 Nov 21
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
7:57am
8-K
xn9fjg
17 Sep 21
Departure of Directors or Certain Officers
8:32am
8-K
seoozcldj
12 Aug 21
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update
10:41am